Log in

SCNX Scienture Holdings, Inc. NASDAQ · United States

Scienture Holdings (SCNX) news

Latest Scienture Holdings news

  1. Company Updates

    Scienture reports second quarter 2026 revenue of $343,639

    Revenue rose from $56,325 in the first quarter, gross margin was approximately 97.7% and the net loss narrowed to about $2.8 million. The company began commercial launch of REZENOPY during the quarter.

  2. Company Updates

    Scienture CFO resigns and Narasimhan Mani named interim CFO

    Eric Sherb resigned as chief financial officer on May 26, 2026. Dr. Narasimhan Mani, already a director and Co-Chief Executive Officer, took the interim role the same day.

  3. Company Updates

    Scienture reports Q1 2026 revenue of $56 thousand and a 95.6% gross margin

    Revenue rose 449% from a year earlier on more Arbli orders. The company also reported $11.0 million of non-dilutive debt financing.

  4. Debt Financing

    Scienture closes $8 million note purchase with Streeterville Capital

    The April 27, 2026 agreement issued an A-1 note and a B note to Streeterville Capital, LLC. Maxim Group LLC served as placement agent.

Scienture Holdings annual financials

LineFY2025FY2024
Research and development$2.0 million$2.2 million
Net income (loss)-$41.5 million$9.1 million
Cash from operations-$13.4 million-$14.3 million
Cash and equivalents$6.7 million$308,096

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $8.2 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Scienture Holdings

What is the ticker symbol of Scienture Holdings?

Scienture Holdings, Inc. trades under the ticker SCNX on NASDAQ.

Where is Scienture Holdings listed?

Scienture Holdings, Inc. is listed on NASDAQ.

Which country or territory is Scienture Holdings listed under?

Our directory records Scienture Holdings, Inc. under United States.

Does aibio.space cover Scienture Holdings?

aibio.space lists Scienture Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Is Scienture Holdings profitable?

Scienture Holdings, Inc. reported a net loss of $41.5 million for the fiscal year ended Dec 31, 2025, and used $13.4 million of cash in operations, per its annual report to the SEC.

How much does Scienture Holdings spend on research and development?

$2.0 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Scienture Holdings have?

$8.2 million in cash at Jun 30, 2026, per its 10-Q.

What is the latest Scienture Holdings (SCNX) stock news?

Our latest story on Scienture Holdings, dated Oct 13, 2026: "Scienture expects preliminary third-quarter revenue of about $1.22 million". Preliminary revenue rose 256% from the second quarter after the REZENOPY launch and higher Arbli wholesale unit sales. The figures are unaudited. Source.

Does Scienture Holdings have debt, a term loan or convertible notes?

Our latest debt story, dated Apr 27, 2026: "Scienture closes $8 million note purchase with Streeterville Capital". The April 27, 2026 agreement issued an A-1 note and a B note to Streeterville Capital, LLC. Maxim Group LLC served as placement agent. Source.

How can I follow Scienture Holdings (SCNX) news?

Press Follow on this page to add Scienture Holdings to your Following list, or subscribe to the aibio.space newsletter. We have published 5 stories naming Scienture Holdings so far, in Company Updates, Debt Financing.

Investor discussion: Scienture Holdings

Members talk about Scienture Holdings (SCNX). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Scienture Holdings, newest first. Each line links the filing it comes from.

  1. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,3.01,9.01). Source

  2. Listings

    Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:SCNX on TradingView.

Listing details

Scienture Holdings, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SCNX, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Scienture Holdings, Inc.
Ticker
SCNX
Listing
NASDAQ
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.